The Problem of Alternative Therapies in Autism

The Neurology of Autism

Volumn , Issue , 2005, Pages

  Pavone, Lorenzo ^a   Ruggieri, Martino ^a,b  

^a UNIVERSITY OF CATANIA   (Italy)

^b CNR   (Italy)

Author keywords

Alternative therapies; Autism; Craniosacral therapy; Diet therapy; Homeopathy; Serotonin; Treatment

Indexed keywords

EID: 84920411178     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1093/acprof:oso/9780195182224.003.0009     Document Type: Chapter

References (123)

1. Ahearn WH, Castine T, Nault K, Green G (2001) An assessment of food acceptance in children with autism or pervasive developmental disorder-not-otherwise specified. Journal of Autism and Developmental Disorders 31:505-511.
2. Aman MG, Lam KS, Collier-Crespin A (2003) Prevalence and patterns of use of psychoactive medicines among individuals with autism in the Autism Society of Ohio. Journal of Autism and Developmental Disorders 33:527-534.
3. American Academy of Pediatrics (1982) Policy statement: The Doman-Delacato treatment of neurologically handicapped children Pediatrics 70:810-812.
4. American Academy of Pediatrics and American Academy of Neurology (1967) Joint executive board statement: Doman-Delacato treatment of neurologically handicapped children. Neurology 17:637.
5. Arnold GL, Hyman SL, Mooney RA, Kirby RS (2003) Plasma amino acids profiles in children with autism: potentials risk of nutritional deficiencies. Journal of Autism and Developmental Disorders 33:449-454.
6. Ashwood P, Anthony A, Pellicer AA, Torrente F, Walker-Smith JA, Wakefield AJ (2003) Intestinal lymphocyte populations in children with regressive autism: evidence for extensive mucosal immunopatholgy. Journal of Clinical Immunology 23:504-517.
7. Asperger H (1961) Die Psychopatologie des coeliank-iekranken Kindes. Annales Paediatriae 197:146-151.
8. Baghdadli A, Gonnier V, Aussilloux C (2002) Review of psychopharmacological treatments in adolescents and adults with autistic disorders. Encephale 28:248-254.
9. Baieli S, Pavone L, Meli C, Fiumara A, Coleman M (2003) Autism and phenylketonuria. Journal of Autism and Developmental Disorders 33:201-204.
10. Barthelemy C, Garreau B, Leddet I, Sauvage D, Domenech J, Muh JP, Lelord G (1980) Biological and clinical effects of oral magnesium and associated magnesium-vitamin B6 administration on certain disorders observed in infantile autism. Therapie 35: 627-632.
11. Barthelemy C, Garreau B, Leddet I, Sauvage D, Muh JP, Lelord G, Callaway E (1983) Value of bahaviour scales and urinary homovanillic acid determination monitoring the combined treatment with vitamin B6 and magnesium in children displaying autistic behaviour. Neuropsychiatrie de l'Enfance et de l'Adolescence 31:289-301.
12. Benda CE (1960) Childhood schizophrenia, autism and Heller's disease. In Proceedings of the First International Metabolic Conference, Portland, Maine. New York: Grune & Stratton.
13. Bettison S (1996) The long-term effects of auditory training on children with autism. Journal of Autism and Developmental Disorders 26:361-374.
14. Bettison S (1997) The long-term effects of auditory training on children with autism. Journal of Autism and Developmental Disorders 27:347-348.
15. Black C, Kaye JA, Jick H (2002) Relation of childhood gastrointestinal disorders to autism: nested case-control study using data from the UK General Practice Research Database. British Medical Journal 325:419-421.
16. Blaxill MF (2004) Concerns continue over mercury and autism. American Journal of Preventive Medicine 26:91; reply 91-92.
17. Blaxill MF, Redwood L, Bernard S (2004) Thimerosal and autism? A plausible hypothesis that should not be dismissed. Medical Hypotheses 62:788-794.
18. Bliumina MG (1975) A schizophrenic-like variant of phenylketonuria. Zhurnail Nevropthologii I Psikiatrii Imeni S S Korsakova 75:1525-1529.
19. Bonisch E (1968) Ehrfarungen met Pyrithioxin bei hirgeschadigten kindern mit autistischen Syndrom. Praxis de Kinderpsychologie 8:308-310.
20. Bowers L (2002) An audit of referrals of children with autistic spectrum disorders to the dietetic service. Journal of Human Nutrition and Dietetics 15:141-144.
21. Braffet C (1994) No milk, no bread please. Autism Society of Indiana Quarterly 1:7-9.
22. Brownell MD (2002) Musically adapted social stories to modify behaviours in students with autism: four case studies. Journal of Musical Therapy 39:117-144.
23. Brudnak MA (2002) Probiotics as an adjuvant to detoxification protocols. Medical Hypotheses 58(5):382-385.
24. Bujas-Petkovic Z, Matjiasic R, Divcic B (1989) Rett's syndrome-differential diagnosis of autism in a case report. Lijek Vjesn 111:458-460.
25. Callaway E (1977) Response of infantile autism to large doses of B6. Psychological Bulletin 13:57-58.
26. Carey T, Ratliff-Scaub K, Funk J, Weinle C, Myers M, Jenks J (2002) Double-blind placebo-controlled trial of secretin: effects on aberrant behavior in children with autism Journal of Autism and Developmental Disorders 32:161-167.
27. Chez MG, Buchanan CP, Bagan BT, Hammer MS, McCarthy KS, Ovrutskaya I, Nowiski I, Cohen ZS (2000) Secretin and autism: a two-part clinical investigation. Journal of Autism and Developmental Disorders 30:87-94.
28. Cohen DJ, Volkmar FR (1997) Handbook of Autism and Pervasive Developmental Disorders. New York: Wiley.
29. Coleman M, Sobel S, Bhagavan HN, Coursin D, Marquardt A, Guay M, Hunt C (1985) A double blind study of vitamin B6 in Down's syndrome infants. Part I. Clinical and biochemical results. Journal of Mental Deficiency Research 29:233-240.
30. Coplan J, Souders MC, Mulberg AE, Belchic JK, Wray J, Jawad AF, Gallagher PI, Mitchell R, Gerdes M, Levy SE (2003) Children with autistic spectrum disorders, II: parents are unable to distinguish secretin from placebo under double-blind conditions. Archives of Disease in Childhood 88:727-739.
31. Delacato CH, Doman G (1957) Hemiplegia and concomitant psychological phenomena. American Journal of Occupational Therapy 11:186-197.
32. Dennis M, Lockyer L, Lazenby AI, Donnelly RE, Wilkinson M, Schoonheyt W (1999) Intelligence patterns among children with high-functioning autism, phenylketonuria, and childhood head injury. Journal of Autism and Developmental Disorders 29:5-17.
33. Dietary supplements seized after autism claims (2003) FDA Consumer Magazine 37:4.
34. Dolske MC, Spollen J, McKay S, Lancashire E, Tolbert L (1993) A preliminary trial of ascorbic acid as supplementary therapy for autism. Progress in Neuropsychopharmacoly and Biological Psychiatry 17:765-774.
35. Doman RJ, Spitz EB, Zucman E, Delacato CH, Doman G (1960) Children with severe brain injuries. Neurological organisation in terms of mobility. JAMA 174:257-262.
36. Dunn-Geier J, Ho HH, Auersperg E, Doyle D, Eaves L, Matsuba C, Orrbine E, Phubes G, Whiting S (2000) Effect of secretin on children with autism: a randomised controlled study. Developmental Medicine and Child Neurology 42:796-802.
37. Edelson SM, Edelson MG, Kerr DC, Grandin T (1999) Behavioural and physiological effects of deep pressure on children with autism: a pilot study evaluating the efficacy of Grand's hug Machine. American Journal of Occupational Therapy 53:145-152.
38. Evangeliou A, Vlachonikolis I, Mihailidou H, Spilloti M, Skarpalezotiou M, Makaronas N, Prokopiou A, Christodoulou P, Liapi-Adamidou G, Helidonis E, Sbyriakis S, Smeitink J (2003) Application of a ketogenic diet in children with autistic behaviour: a pilot study. Journal of Child Neurology 18:113-118.
39. Filipek PA, Accardo PJ, Ashwal S, Baranek GT, Cook EH, Dawson G, Gordon B, Gravel JS, Johnson CP, Kallen RJ, Levy SE, Minshew NJ, OzonoffS, Prizant BM, Rapin I, Rogers SJ, Stone WL, Teplin SW, Tuchman RF, Volkmar FR (2000) Practice parameters: screening and diagnosis of autism. Report of the quality standards subcommittee of the American Academy of Neurology and the Child Neurology Society. Neurology 55:468-479.
40. Findling RL, Maxwell K, Scotese-Wojtila L, Huang J, Yamashita T, Wizniter M (1997) High doses pyridoxine and magnesium administration in children with autistic disorder: an absence of salutary effects in a double-blind, placebo controlled study. Journal of Autism and Developmental Disorders 27:581-578.
41. Fombonne E, du Mazaubrun C (1992) Prevalence of infantile autism in four French regions. Social Psychiatry and Psychiatric Epidemiology 27:203-210.
42. Friedman E (1969) The autistic syndrome and phenylketonuria. Schizophrenia 1:249-261.
43. Garvey J (2002) Diet in autism and associated disorders. Journal of Family Health Care 12:34-38.
44. Gillberg C, Coleman M (2000) The biology of Autistic Syndromes (3rd ed.). Cambridge: Cambridge University Press.
45. Gillberg C, Wahlstrom J, Johansson R, Tornblom M, Albertsson-Wikland K (1986) Folic acid as an adjunct in the treatment of children with the autism-fragile X syndrome (AFRAX). Developmental Medicine and Child Neurology 28:624-627.
46. Gobbi G, Andermann F, Naccarato S, Banchini G (1997). Epilepsy and Other Neurological Disorders in Coeliac Disease. London: John Libbey.
47. Goodwin MS, Cowen MA, Goodwin TC (1971) Malabsorption and cerebral dysfunction. A multivariate and comparative study of autistic children. Journal of Autism and Childhood Schizophrenia 1:48.
48. Goodwin MS, Goodwin TC (1969) In a dark mirror. Mental Hygiene 53:550.
49. Haas RH, Rice MA, Trauner DA, Merritt TA (1986) Therapeutic effects of a Ketogenic diet in Rett syndrome. American Journal of Medical Genetics 1(Suppl):225-246.
50. Hadjivassiliou M, Boscolo S, Davies-Jones GAB (2002) The humoral response in the pathogenesis of gluten ataxia. Neurology 58:1221-1226.
51. Heely AF, Roberts GE (1966) A study of tryptophan metabolism in psychotic children. Developmental Medicine and Child Neurology 8:708-718.
52. Holmes AS, Blaxill MF, Haley BE (2003) Reduced levels of mercury in first baby haircuts of autistic children. International Journal of Toxicology 22:277-285.
53. Horwath K, Stefanatos G, Sololski KN, Watchel R, Nabors L, Tildon JT (1998) Improved social and language skills after secretin administration in patients with a autism spectrum disorders. Journal of the Association for Academic Minority Physicians 9:9-15.
54. Howlin P (1997) Prognosis in autism: do specialist treatments affect long-term outcome? European Child and Adolescent Psychiatry 6:55-72.
55. Jyonouchi H, Sun S, Itokazu N (2002) Innate immunity associated with inflammatory responses and cytokine production against common dietary proteins in patients with autism spectrum disorders. Neuropsychobiology 46:76-84.
56. Kanner L (1942-43) Autistic disturbances of affective contact. Nervous Child 2:217-250.
57. Kidd PM (2003) An approach to the nutritional management of autism. Alternative Therapies in Health and Medicine 9:22-31; quiz 32, 126.
58. Kidd PM (2002) Autism, an extreme challenge to integrative medicine. Part 2: medical management. Alternative Medicine Review 7:472-499.
59. Knivsberg AM, Reichelt KL, Hoien T, Nodland M (2002) A randomised controlled study of dietary intervention in autistic syndromes. Nutritional Neuroscience 5:251-261.
60. Knivsberg AM, Reichelt KL, Nodland M (2001) Reports on dietary intervention in autistic disorders. Nutritional Neuroscience 4:25-37.
61. Knobloch H, Pasamanick B (1975) Some etiologic and prognostic factors in early infantile autism and psychosis. Journal of Pediatrics 55:182-191.
62. Lelord G, Callaway E, Muh JP (1982) Clinical and biological effects of high doses of vitamin B6 and magnesium on autistic children. Acta Vitaminologica Enzymologica 4:27-44.
63. Lelord G, Muh JP, Barthelemy C, Martineau J, Garreau B, Callaway E (1981) Effects of pyridoxine and magnesium on autistic symptoms-initial observations. Journal of Autism and Developmental Disorders 11:219-230.
64. Lerner V, Miodownik C, Kaptsan A, Cohen H, Loewenthal U, Kotler M (2002) Vitamin B6 as add-on treatment in chronic schizophrenic and schizoaffective patients: a double-blind, placebo-controlled study. Journal of Clinical Psychiatry 63:54-58.
65. Levine J, Aviram A, Holan A, Ring A, Barak Y, Belmaker RH (1997) Inositol treatment of autism. Journal of Neural Transmission 104:307-310.
66. Levy SE, Hyman SL (2003) Use of complementary and alternative treatments for children with autism spectrum disorders is increasing. Annales de Pediatrie 32:685-691.
67. Levy SE, Sounders MC, Wray J, Jawad AF, Gallagher PR, Coplan J, Belchic JK, Gerdes M, Mitchell R, Mulberg AE (2003) Children with autistic spectrum disorders, I: comparison of placebo vs. single dose of human syntethic secretin. Archives of Disease in Childhood 88:731-736.
68. Lewis E (1959) The development of concepts in girls with dietary treatment of phenylketonuria. Journal of Medical Psychology 32:282-287.
69. Lowe TL, Cohen DJ, Miller S, Young JG (1981) Folic acid and B12 in autism and neuropsychiatric disturbances of childhood. Journal of the American Academy of Child Psychiatry 20:104-111.
70. Lowe TL, Tanaka K, Seashore MR, Young JG, Cohen DJ (1980) Detection of phenylketonuria in autistic and psychotic children. JAMA 243:126-128.
71. Madsen KM, Lauritsen MB, Pedersen CB, Thorsen P, Plesner AM, Andersen PH, Mortensen PB (2003) Thimerosal and the occurrence of autism: negative ecological evidence from Danish population-based data. Pediatrics 112:604-606.
72. Maki M, Mustalahti K, Kokkonen J (2003). Prevalence of celiac disease among children in Finland. New England Journal of Medicine 348:2517-2524.
73. Martineau J, Barthelemy C, Garreau B, Lelord G (1985) Vitamin B6, magnesium, and combined B6-Mg: therapeutic effects in childhood autism. Biological Psychiatry 20: 467-478.
74. Martineau J, Garreau B, Barthelemy C, Callaway E, Lelord G (1981) Effects of vitamin B6 on averaged evoked potentials in infantile autism. Biological Psychiatry 16:627-641.
75. McCarthy DM, Coleman M (1979) Response of intestinal mucosa to gluten challenge in autistic subjects. Lancet ii:877-878.
76. McDougle CJ, Naylor ST, Cohen DJ, Aghanjanian GK, Heninger GR, Price LH (1996) Effects of tryptophan depletion in drug-free adults with autistic disorder. Archives of General Psychiatry 53:993-1000.
77. McDougle CJ, Naylor ST, Goodman WK, Volkamr FR, Cohen DJ, Price LH (1993) Acute tryptophan depletion in autistic disorder: a controlled study. Biological Psychiatry 33:547-550.
78. McFadden SA (1996) Phenotypic variation in xenobiotic metabolism and adverse environmental response: focus on sulfur-dependent detoxification pathways. Toxicology 111:43-65.
79. Megson MN (2000) Is autism a G-alpha protein defect reversible with natural vitamin A? Medical Hypotheses 54:979-983.
80. Millward C, Ferriter M, Calver S, Connell-Jones G (2004) Gluten-and casein-free diets for autistic spectrum disorder. The Cochrane Database of Systematic Reviews 2:CD003498.
81. Molloy CA, Manning-Courtney P, Swayne S, Bean J, Brown JM, Murray DS, Kinsman AM, Brasinghton M, Ulrich CD 2nd (2002) Lack of benefit of intravenous human secretin in the treatment of autism. Journal of Autism and Developmental Disorders 32:545-551.
82. Moss N, Boverman H (1978) Megavitamin therapy for autistic children. American Journal of Psychiatry 135:1425-1426.
83. Mudford OC, Cross BA, Breen S, Cullen C, Reeves D, Gould J, Douglas J (2000) Auditory integration training for children with autism: no behavioural benefits detected. American Journal of Mental Retardation 105:118-129.
84. National Research Council (2001) Educating Young Children With Autism. Washington, DC: National Academic Press.
85. Nelson KB, Grether JK, Croen LA, Dambrosia JM, Dickens BF, Jelliffe LL, Hansen RL, Phillips TM (2001) Neuropeptides and neurotrophins in neonatal blood of children with autism or mental retardation. Annals of Neurology 49:597-606.
86. Nye C, Brice A (2002) Combined vitamin B6-magnesium treatment in autism spectrum disorders. The Cochrane Database of Systematic Reviews 4:CD003497.
87. Padhye U (2003) Excess dietary iron is the root cause for increase in childhood autism and allergies. Medical Hypotheses 61:220-222.
88. Page T (2000) Metabolic approaches to the treatment of autism spectrum disorders. Journal of Autism and Developmental Disorders 30:463-469.
89. Patel NC, Yeh JY, Shepherd MD, Crismon ML (2002) Secretin treatment for autistic disorder: a critical analysis. Pharmacotherapy 22:905-914.
90. Pavone L, Fiumara A, Bottaro G, Mazzone D, Coleman M (1997) Autism and celiac disease: failure to validate the hypothesis that a link might exist. Biological Psychiatry 42:72-75.
91. Raiten DJ, Massaro T (1986) Perspectives on the nutritional ecology of autistic children. Journal of Autism and Developmental Disorders 16:133-144.
92. Rapin I. (2002) The autistic spectrum disorders. New England Journal of Medicine 347:302-303.
93. Reichelt KL, Sarlid G, Lindback T, Boler JB (1986) Childhood autism: a complex disorder. Biological Psychiatry 21:1279-1290.
94. Reiss AL, Feinstein C, Rosenbaum KN (1986) Autism in genetic disorders. Sia Bulletin 12:724-738.
95. Rimland B (1972) Progress in research. Proceedings of the Fourth Annual Meeting of the National Society for Autistic Children, Washington, DC.
96. Rimland B (1988) Controversies in the treatment of austistic children: vitamin and drug therapy. Journal of Child Neurology 3 Suppl:S68-S72.
97. Rimland B (1998) High dose vitamin B6 and magnesium in treating autism: response to study by Findling et al. Journal of Autism Developmental Disorders 28:581-582.
98. Rimland B, Callaway E, Dreyfus P (1978) The effect of high doses of vitamin B6 on autistic children: a double-blind crossover study. American Journal of Psychiatry 135:472-475.
99. Rimland B, Edelson SM (1995) Brief report: a pilot study of auditory integration training in autism. Journal of Autism and Developmental Disorders 25:61-70.
100. Rimland B, Ney PG (1974) Infantile autism: status of research. Canadian Psychiatry Association 19:130-135.
101. Sandler AD, Bodfish JW (2000) Placebo effect sin autism: lessons from secretin. Journal of Developmental and Behavioral Pedriatrics 21:347-350.
102. Sandler AD, Sutton KA, DeWeese J, Girard MA, Sheppard V, Bodfish JW (1999) Lack of benefit of a single dose of synthetic human secretin in the treatment of autism and pervasive developmental disorders. New England Journal of Medicine 341:1801-1806.
103. Sankar DVS (1979) Plasma levels of folates, riboflavin, vitamin B6 and ascorbate in severely disturbed children. Journal of Autism and Developmental Disorders 9:73-82.
104. Schaumberg H, Kaplan J, Windebank A, Vick N, Rasmus S, Pleasure D, Brown MJ (1983) Sensory neuropathy from pyridoxine abuse. New England Journal of Medicine 309:445-458.
105. Shattock P (1988) Autism: possible clues to the underlying aetiology. A parent's view. In Wing L (Ed) Aspects of Autism (pp. 1-18). London: Gaskell.
106. Sinha Y, Silove N, Wheeler D, Williams K (2004) Auditory integration training and other sound therapies for autism spectrum disorders. The Cochrane Database of Systematic Reviews CD003681.
107. Sourander A, Ellila H, Valimaki M, Piha J (2002) Use of holding, restraints, seclusion and time-out in child and adolescent psychiatric in-patient treatment. European Journal of Adolescent Psychiatry 11:162-167.
108. Sponheim E, Oftedal G, Helverschou SB (2002) Multiple doses of secretin in the treatment of autism: a controlled study. Acta Paediatrica 91:540-545.
109. Stehr-Green P, Tull P, Stellfeld M, Mortensen PB, Simpson D (2003) Autism and thimerosal-containing vaccines: lack of consistent evidence for an association. American Journal of Preventive Medicine 25:101-106.
110. Sullivan R (1975) Hunches on some biological factors in autism. Journal of Autism and Child Schizophrenia 5:177-184.
111. Tolbert L, Haigler T, Waits MM, Dennis T (1993) Brief report: Lack of response in an autistic population to a low dose clinical trial of pyridoxine plus magnesium. Journal of Autism and Developmental Disorders 23:193-199.
112. Ulshen M (2004) Malabsorptive disorders. In Behrman RE, Kliegman RM, Jenson HB (Eds) Nelson Textbook of Pediatrics (17th ed.) (pp. 1159-1171). Philadelphia: W.B. Saunders.
113. Unis AS, Munson JA, Rogers SJ, Goldson E, Osterling J, Gabriels R, Abbott RD, Dawson G (2002) A randomized, double-blind, placebo-controlled trial of porcine versus synthetic secretin for reducing symptoms of autism. Journal of the American Academy of Child Psychiatry 41:1315-1321.
114. Vanhala R, Turpeinen U, Riikonen R (2001) Low levels of insulin-like growth factor-I in cerebrospinal fluid in children with autism. Developmental Medicine and Child Neurology 43:614-616.
115. Veale D (1993) Classification and treatment of obsessional slowness. British Journal of Psychiatry 162:198-203.
116. Verstraeten T, Davis RL, DeStefano F, Lieu TA, Rhodes PH, Black SB, Shinefield H, Chen RT (2003) Vaccine Safety Datalink Team. Pediatrics 112:1039-1048.
117. Vining EPG, Kossoff EH (2004) The Ketogemic diet. In Wallace SS, Forrell K (Eds). Epilepsy in Children. London: Arnold: 405-408.
118. Volkmar FR, Pauls D (2003) Autism. Lancet 362:1133-1141.
119. Walker-Smith J (1973) Gastrointestinal disease and autism-the result of a survey. Symposium on Autism, Sidney, Australia. Abbott Laboratories.
120. Welch MG, Keune JD, Welch-Horan TB, Anwar N, Ludwig RJ, Ruggiero DA (2004) Secretin: hypothalamic distribution and hypothesised neuroregulation in autism. Cellular and Molecular Neurobiology 24:219-241.
121. Wilder RM (1921) The effects of ketonemics on the course of epilepsy. Mayo Clinic Proceedings 2:307-308.
122. Williams K (1998) Benefits of normalising plasma phenylalanine: impact of behaviour and health. A case report. Journal of Inherited Metabolic Disease 21:785-790.
123. Yamagata T, Aradhya S, Mori M, Inoue K, Momoi MY, Nelson DL (2002) The human secretin gene: fine structure in 11p15.5 and sequence variability in patients with autism. Genomics 80:185-194.